Mo Qatanani Biography and Net Worth

Insider of Scholar Rock

Mo Qatanani joined Scholar Rock in 2021 and has served as Chief Scientific Officer since 2024. He is responsible for all research functions, including discovery biology, protein sciences & antibody engineering, safety and translational sciences. Mo brings more than 15 years of discovery and translational research experience in developing and advancing multiple therapeutic modalities across many disease areas in the biotech and pharmaceutical industry. Prior to Scholar Rock, Mo was a founding employee, vice president, and Head of Research at Dyne Therapeutics, where he built the research organization from the ground up to launch and advance to the clinic multiple therapeutic programs for rare neuromuscular diseases. Prior to Dyne, Mo held research positions of increasing responsibility at Alexion Pharmaceuticals, Synageva BioPharma, and Merck. Mo holds a Ph.D. in molecular and human genetics from Baylor College of Medicine and completed a post-doctoral fellowship at the University of Pennsylvania School of Medicine. He has a B.Sc. and a M.Sc. in Biology from the American University of Beirut.

What is Mo Qatanani's net worth?: The estimated net worth of Mo Qatanani is at least $3.65 million as of February 19th, 2025. Dr. Qatanani owns 111,084 shares of Scholar Rock stock worth more than $3,647,999 as of March 30th. This net worth evaluation does not reflect any other investments that Dr. Qatanani may own. Learn More about Mo Qatanani's net worth.
How old is Mo Qatanani?: Dr. Qatanani is currently 51 years old. There are 6 older executives and no younger executives at Scholar Rock. The oldest executive at Scholar Rock is Dr. Jay Thomas Backstrom M.D., M.P.H., President, CEO & Director, who is 69 years old. Learn More on Mo Qatanani's age.
How do I contact Mo Qatanani?: The corporate mailing address for Dr. Qatanani and other Scholar Rock executives is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. Scholar Rock can also be reached via phone at (857) 259-3860 and via email at chu@scholarrock.com. Learn More on Mo Qatanani's contact information.
Has Mo Qatanani been buying or selling shares of Scholar Rock?: In the last ninety days, Mo Qatanani has sold $2,562,274.00 in shares of Scholar Rock stock. Most recently, Mo Qatanani sold 68,510 shares of the business's stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $37.40, for a transaction totalling $2,562,274.00. Following the completion of the sale, the insider now directly owns 111,084 shares of the company's stock, valued at $4,154,541.60. Learn More on Mo Qatanani's trading history.
Who are Scholar Rock's active insiders?: Scholar Rock's insider roster includes Srinivas Akkaraju (Director), Jay Backstrom (President & CEO), Jeffrey Flier (Director), Junlin Ho (General Counsel & Corporate Secretary), Jing Marantz (Chief Medical Officer), Edward Myles (CFO), Caryn Parlavecchio (Insider), Katie Peng (Chief Commercial Officer, Denali Therapeutics), Mo Qatanani (Insider), and Tracey Sacco (Chief Commercial Officer). Learn More on Scholar Rock's active insiders.
Are insiders buying or selling shares of Scholar Rock?: In the last year, insiders at the sold shares 20 times. They sold a total of 2,141,013 shares worth more than $67,818,845.02. The most recent insider tranaction occured on March, 24th when insider Tracey Sacco sold 6,500 shares worth more than $215,020.00. Insiders at Scholar Rock own 19.2% of the company. Learn More about insider trades at Scholar Rock.
Information on this page was last updated on 3/24/2025.

Mo Qatanani Insider Trading History at Scholar Rock

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/19/2025	Sell	68,510	$37.40	$2,562,274.00	111,084
9/16/2024	Sell	1,936	$8.58	$16,610.88	142,768
6/17/2024	Sell	2,315	$8.98	$20,788.70	144,704
2/16/2024	Sell	2,512	$15.74	$39,538.88	147,019
1/16/2024	Sell	2,002	$15.93	$31,891.86	78,816
9/18/2023	Sell	1,945	$6.34	$12,331.30	97,043

Mo Qatanani Buying and Selling Activity at Scholar Rock

Scholar Rock Company Overview

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $32.84

$32.03

$33.96

50 Day Range

MA: $37.74

$32.16

$46.73

2 Week Range

Now: $32.84

$6.76

$46.98

Volume

1,129,184 shs

Average Volume

1,171,222 shs

Market Capitalization

$3.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59

Mo Qatanani Biography and Net Worth

What is Mo Qatanani's net worth?

How old is Mo Qatanani?

How do I contact Mo Qatanani?

Has Mo Qatanani been buying or selling shares of Scholar Rock?

Who are Scholar Rock's active insiders?

Are insiders buying or selling shares of Scholar Rock?